Search

Your search keyword '"Jacqz‐Aigrain, Evelyne"' showing total 871 results
Start Over Author "Jacqz‐Aigrain, Evelyne"
871 results on '"Jacqz‐Aigrain, Evelyne"'

2. Use of Machine Learning for Dosage Individualization of Vancomycin in Neonates

Author

Tang, Bo-Hao, Zhang, Jin-Yuan, Allegaert, Karel, Hao, Guo-Xiang, Yao, Bu-Fan, Leroux, Stephanie, Thomson, Alison H., Yu, Ze, Gao, Fei, Zheng, Yi, Zhou, Yue, Capparelli, Edmund V., Biran, Valerie, Simon, Nicolas, Meibohm, Bernd, Lo, Yoke-Lin, Marques, Remedios, Peris, Jose-Esteban, Lutsar, Irja, Saito, Jumpei, Jacqz-Aigrain, Evelyne, van den Anker, John, Wu, Yue-E., and Zhao, Wei

Published
2023
Full Text
View/download PDF

6. Modalités pratiques de prise en charge en cours de traitement d’entretien des leucémies aiguës lymphoblastiques pédiatriques : recommandations du Comité leucémies de la Société française de lutte contre les cancers et les leucémies de l’enfant et de l’adolescent (SFCE)

Author

Saultier, Paul, Simonin, Mathieu, Beaumais, Tiphaine Adam de, Rialland, Fanny, Alby-Laurent, Fanny, Lubnau, Marion, Desplantes, Claire, Jacqz-Aigrain, Evelyne, Rohrlich, Pierre, Reguerre, Yves, Rabian, Florence, Sirvent, Nicolas, Plat, Geneviève Willson, and Petit, Arnaud

Published
2022
Full Text
View/download PDF

7. Agreement between a regional pharmacovigilance centre and an adjudication committee regarding adverse drug reactions on a cohort of hospitalised children

Author

Pages, Nicolas, Bounabi, Anissa, Boussaha, Inesse, Ndiaye, Marietou, Portefaix, Aurélie, Simeon, Gaelle, Guy, Claire, Stagnara, Jean, Paret, Nathalie, Vial, Thierry, Eftekhari, Pirayeh, Floret, Daniel, Gajdos, Vincent, Langhendries, Jean-Paul, Bleyzac, Nathalie, Alberti, Corinne, Jacqz-Aigrain, Evelyne, Nguyen, Kim An, and Kassai, Behrouz

Published
2022
Full Text
View/download PDF

9. Drug Clearance in Neonates: A Combination of Population Pharmacokinetic Modelling and Machine Learning Approaches to Improve Individual Prediction

Author

Tang, Bo-Hao, Guan, Zheng, Allegaert, Karel, Wu, Yue-E., Manolis, Efthymios, Leroux, Stephanie, Yao, Bu-Fan, Shi, Hai-Yan, Li, Xiao, Huang, Xin, Wang, Wen-Qi, Shen, A.-Dong, Wang, Xiao-Ling, Wang, Tian-You, Kou, Chen, Xu, Hai-Yan, Zhou, Yue, Zheng, Yi, Hao, Guo-Xiang, Xu, Bao-Ping, Thomson, Alison H., Capparelli, Edmund V., Biran, Valerie, Simon, Nicolas, Meibohm, Bernd, Lo, Yoke-Lin, Marques, Remedios, Peris, Jose-Esteban, Lutsar, Irja, Saito, Jumpei, Burggraaf, Jacobus, Jacqz-Aigrain, Evelyne, van den Anker, John, and Zhao, Wei

Published
2021
Full Text
View/download PDF

11. A physiological approach to renal clearance:From premature neonates to adults

Author

Holford, Nick, O'Hanlon, Conor J., Allegaert, Karel, Anderson, Brian, Falcao, Amilcar, Simon, Nicolas, Lo, Yoke-Lin, Thomson, Alison H., Sherwin, Catherine M., Jacqz-Aigrain, Evelyne, Llanos-Paez, Carolina, Hennig, Stefanie, Mockus, Linas, Kirkpatrick, Carl, Holford, Nick, O'Hanlon, Conor J., Allegaert, Karel, Anderson, Brian, Falcao, Amilcar, Simon, Nicolas, Lo, Yoke-Lin, Thomson, Alison H., Sherwin, Catherine M., Jacqz-Aigrain, Evelyne, Llanos-Paez, Carolina, Hennig, Stefanie, Mockus, Linas, and Kirkpatrick, Carl

Abstract

Aims: We propose using glomerular filtration rate (GFR) as the physiological basis for distinguishing components of renal clearance. Methods: Gentamicin, amikacin and vancomycin are thought to be predominantly excreted by the kidneys. A mixed-effects joint model of the pharmacokinetics of these drugs was developed, with a wide dispersion of weight, age and serum creatinine. A dataset created from 18 sources resulted in 27,338 drug concentrations from 9,901 patients. Body size and composition, maturation and renal function were used to describe differences in drug clearance and volume of distribution. Results: This study demonstrates that GFR is a predictor of two distinct components of renal elimination clearance: (1) GFR clearance associated with normal GFR and (2) non-GFR clearance not associated with normal GFR. All three drugs had GFR clearance estimated as a drug-specific percentage of normal GFR (gentamicin 39%, amikacin 90% and vancomycin 57%). The total clearance (sum of GFR and non-GFR clearance), standardized to 70 kg total body mass, 176 cm, male, renal function 1, was 5.58 L/h (95% confidence interval [CI] 5.50-5.69) (gentamicin), 7.77 L/h (95% CI 7.26-8.19) (amikacin) and 4.70 L/h (95% CI 4.61-4.80) (vancomycin). Conclusions: GFR provides a physiological basis for renal drug elimination. It has been used to distinguish two elimination components. This physiological approach has been applied to describe clearance and volume of distribution from premature neonates to elderly adults with a wide dispersion of size, body composition and renal function. Dose individualization has been implemented using target concentration intervention.

Published
2024

14. A physiological approach to renal clearance: From premature neonates to adults.

Author

Holford, Nick, O'Hanlon, Conor J., Allegaert, Karel, Anderson, Brian, Falcão, Amilcar, Simon, Nicolas, Lo, Yoke‐Lin, Thomson, Alison H., Sherwin, Catherine M., Jacqz‐Aigrain, Evelyne, Llanos‐Paez, Carolina, Hennig, Stefanie, Mockus, Linas, and Kirkpatrick, Carl

Subjects
PREMATURE infants, NEWBORN infants, ADULTS, KIDNEY physiology, GLOMERULAR filtration rate, BODY composition
Abstract

Aims: We propose using glomerular filtration rate (GFR) as the physiological basis for distinguishing components of renal clearance. Methods: Gentamicin, amikacin and vancomycin are thought to be predominantly excreted by the kidneys. A mixed‐effects joint model of the pharmacokinetics of these drugs was developed, with a wide dispersion of weight, age and serum creatinine. A dataset created from 18 sources resulted in 27,338 drug concentrations from 9,901 patients. Body size and composition, maturation and renal function were used to describe differences in drug clearance and volume of distribution. Results: This study demonstrates that GFR is a predictor of two distinct components of renal elimination clearance: (1) GFR clearance associated with normal GFR and (2) non‐GFR clearance not associated with normal GFR. All three drugs had GFR clearance estimated as a drug‐specific percentage of normal GFR (gentamicin 39%, amikacin 90% and vancomycin 57%). The total clearance (sum of GFR and non‐GFR clearance), standardized to 70 kg total body mass, 176 cm, male, renal function 1, was 5.58 L/h (95% confidence interval [CI] 5.50‐5.69) (gentamicin), 7.77 L/h (95% CI 7.26‐8.19) (amikacin) and 4.70 L/h (95% CI 4.61‐4.80) (vancomycin). Conclusions: GFR provides a physiological basis for renal drug elimination. It has been used to distinguish two elimination components. This physiological approach has been applied to describe clearance and volume of distribution from premature neonates to elderly adults with a wide dispersion of size, body composition and renal function. Dose individualization has been implemented using target concentration intervention. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Key factors associated with 6‐thioguanine and 6‐methylmercaptopurine nucleotide concentrations in children treated by thiopurine for acute leukaemia and inflammatory bowel disease.

Author

de Beaumais, Tiphaine Adam, Lorrain, Simon, Mamhoudi, Naura, Simonin, Mathieu, Martinez Vinson, Christine, Medard, Yves, Petit, Arnaud, and Jacqz‐Aigrain, Evelyne

Subjects
INFLAMMATORY bowel diseases, AZATHIOPRINE, ACUTE leukemia, DRUG monitoring, LYMPHOBLASTIC leukemia, ERYTHROCYTES
Abstract

Aims: Azathioprine (AZA) and 6‐mercaptopurine are prescribed in acute lymphoblastic leukaemia (ALL) and inflammatory bowel diseases (IBD). Metabolism to active 6‐thioguanine (6TGN) and 6‐methylmercaptopurine nucleotides (6MMPN) is variable but therapeutic drug monitoring (TDM) remains debatable. This study reports on factors impacting on red blood cell (RBC) metabolites concentrations in children to facilitate TDM interpretation. Methods: The first paediatric TDM samples received during year 2021 were analysed, whatever indication and thiopurine drug. Target concentration ranges were 200–500, <6000 pmol/8 × 108 RBC for 6TGN and 6MMPN. Results: Children (n = 492) had IBD (64.8%), ALL (22.6%) or another autoimmune disease (12.6%): mean ages at TDM were 7.5 in ALL and 13.7 years in IBD (P <.0001). ALL received 6‐mercaptopurine (mean dose 1.7 mg/kg/d with methotrexate), IBD received AZA (1.9 mg/kg/d with anti‐inflammatory drugs and/or monoclonal antibodies). Median 6TGN and 6MMPN concentrations were 213.7 [interquartile range: 142.5; 309.6] and 1144.6 [419.4; 3574.3] pmol/8 × 108 RBC, 38.8% of patients were in the recommended therapeutic range for both compounds. Aminotransferases and blood tests were abnormal in 57/260 patients: 8.1% patients had high alanine aminotransaminase, 3.4% of patients had abnormal blood count. Factors associated with increased 6TGN were age at TDM and thiopurine methyltransferase genotype in ALL and AZA dose in IBD. The impact of associated treatment in IBD patients was also significant. Conclusion: TDM allowed identification of children who do not reach target levels or remain over treated. Including TDM in follow‐up may help physicians to adjust dosage with the aim of reducing adverse effects and improve treatment outcome. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Safety study of Ciprofloxacin in newborn mice

Author

Bourgeois, Thomas, Delezoide, Anne-Lise, Zhao, Wei, Guimiot, Fabien, Adle-Biassette, Homa, Durand, Estelle, Ringot, Maud, Gallego, Jorge, Storme, Thomas, Le Guellec, Chantal, Kassaï, Behrouz, Turner, Mark A., Jacqz-Aigrain, Evelyne, and Matrot, Boris

Published
2016
Full Text
View/download PDF

27. Favorable pharmacokinetics and pharmacodynamics properties of Gilteritinib in cerebrospinal fluid: a potential effective treatment in relapsing meningeal acute myeloid leukaemia FLT3-ITD patients

Author

Vignal, Nicolas, primary, Kelly, Loïs, additional, Lengline, Etienne, additional, Cabannes-Hamy, Aurélie, additional, Siavellis, Justine, additional, Ghez, David, additional, Sauvageon, Hélène, additional, Braun, Thorsten, additional, Jacqz-Aigrain, Evelyne, additional, Kohn, Milena, additional, Rousselot, Philippe, additional, Puissant, Alexandre, additional, Raffoux, Emmanuel, additional, Mourah, Samia, additional, and Goldwirt, Lauriane, additional

Published
2023
Full Text
View/download PDF

37. How paediatric drug development and use could benefit from OMICs:A c4c expert group white paper

Author

Neumann, Eva, Schreeck, Filippa, Herberg, Jethro, Jacqz Aigrain, Evelyne, Maitland-van der Zee, Anke H., Pérez-Martínez, Antonio, Hawcutt, Daniel B., Schaeffeler, Elke, Rane, Anders, de Wildt, Saskia N., Schwab, Matthias, Neumann, Eva, Schreeck, Filippa, Herberg, Jethro, Jacqz Aigrain, Evelyne, Maitland-van der Zee, Anke H., Pérez-Martínez, Antonio, Hawcutt, Daniel B., Schaeffeler, Elke, Rane, Anders, de Wildt, Saskia N., and Schwab, Matthias

Abstract

The safety and efficacy of pharmacotherapy in children, particularly preterms, neonates and infants, is limited by a paucity of good-quality data from prospective clinical drug trials. A specific challenge is the establishment of valid biomarkers. OMICs technologies may support these efforts by complementary information about targeted and nontargeted molecules through systematic characterization and quantitation of biological samples. OMICs technologies comprise at least genomics, epigenomics, transcriptomics, proteomics, metabolomics and microbiomics in addition to the patient's phenotype. OMICs technologies are in part hypothesis-generating, allowing an in depth understanding of disease pathophysiology and pharmacological mechanisms. Application of OMICs technologies in paediatrics faces major challenges before routine adoption. First, developmental processes need to be considered, including a subdivision into specific age groups as developmental changes clearly impact OMICs data. Second, compared to the adult population, the number of patients is limited as are the type and amount of necessary biomaterial, especially in neonates and preterms. Thus, advanced trial designs and biostatistical methods, noninvasive biomarkers, innovative biobanking concepts including data and samples from healthy children, as well as analytical approaches (eg liquid biopsies) should be addressed to overcome these obstacles. The ultimate goal is to link OMICs technologies with innovative analysis tools, such as artificial intelligence at an early stage. The use of OMICs data based on a feasible approach will contribute to the identification complex phenotypes and subpopulations of patients to improve the development of medicines for children with potential economic advantages.

Published
2022

39. Prevalence of herpesviruses at onset of idiopathic nephrotic syndrome

Author

Dossier, Claire, Sellier-Leclerc, Anne-Laure, Rousseau, Alexandra, Michel, Yanne, Gautheret-Dejean, Agnes, Englender, Mariana, Madhi, Fouad, Charbit, Marina, Ulinski, Tim, Simon, Tabassome, Jacqz-Aigrain, Evelyne, and Deschenes, Georges

Subjects
Steroids (Drugs) -- Complications and side effects -- Research, Herpes -- Distribution -- Demographic aspects -- Research, Nephrotic syndrome -- Development and progression -- Demographic aspects -- Research, Herpesvirus diseases -- Distribution -- Demographic aspects -- Research, Company distribution practices, Health
Abstract

Background Idiopathic nephrotic syndrome (INS) is likely a primary immune disorder, but viruses might also be involved in the mechanisms of the disease. Here, we investigate the link between herpesvirus infection and the first manifestation of INS in children. Methods A prospective, multicentre, and population-based case-control study called NEPHROVIR included 164 patients, aged 6 months to 15 years old, newly diagnosed with INS, and 233 controls matched for gender, age, and period of sample. The analysis was done on 124 patients and 196 controls. Epstein-Barr virus (EBV), cytomegalovirus (CMV), human herpesvirus-6 (HHV-6), and human herpesvirus-7 (HHV-7) DNA prev alence at diagnosis were assessed from whole peripheral blood samples, as well as EBV and CMV viral load and seroprevalence. Results EBV DNA was significantly more prevalent in cases than in controls (50.8 vs 29.1 %; OR=2.6; p=0.0002), with no difference in viral load. A significant difference was also found for CMV (11.3 vs 3.6 %; p=0.02) and HHV-7 (83 vs 72 %; p=0.02) DNA prevalence between cases and controls. There were significantly more EBV and CMV recent infections or reactivations based on VCA-IgM and CMV IgM in cases than controls, while there were no differences in IgG seroprevalence. Conclusion The prevalence of positive EBV DNA detection and recent infection or reactivation is higher in children at onset of INS compared to a population matched for age, gender, and time of sampling. Keywords Epstein-barr virus * Cytomegalovirus * Steroid-sensitive nephroticsyndrome * Proteinuria Nephrovir, Introduction Steroid-sensitive idiopathic nephrotic syndrome (INS) is likely a primary immune disorder since proteinuria is fully sensitive to prednisone, and numerous immunosuppressive drugs have the ability to control the occurrence [...]

Published
2014
Full Text
View/download PDF

40. A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotes

Author

Bastard, Paul, primary, Hsiao, Kuang-Chih, additional, Zhang, Qian, additional, Choin, Jeremy, additional, Best, Emma, additional, Chen, Jie, additional, Gervais, Adrian, additional, Bizien, Lucy, additional, Materna, Marie, additional, Harmant, Christine, additional, Roux, Maguelonne, additional, Hawley, Nicola L., additional, Weeks, Daniel E., additional, McGarvey, Stephen T., additional, Sandoval, Karla, additional, Barberena-Jonas, Carmina, additional, Quinto-Cortés, Consuelo D., additional, Hagelberg, Erika, additional, Mentzer, Alexander J., additional, Robson, Kathryn, additional, Coulibaly, Boubacar, additional, Seeleuthner, Yoann, additional, Bigio, Benedetta, additional, Li, Zhi, additional, Uzé, Gilles, additional, Pellegrini, Sandra, additional, Lorenzo, Lazaro, additional, Sbihi, Zineb, additional, Latour, Sylvain, additional, Besnard, Marianne, additional, Adam de Beaumais, Tiphaine, additional, Jacqz Aigrain, Evelyne, additional, Béziat, Vivien, additional, Deka, Ranjan, additional, Esera Tulifau, Litara, additional, Viali, Satupa‘itea, additional, Reupena, Muagututi‘a Sefuiva, additional, Naseri, Take, additional, McNaughton, Peter, additional, Sarkozy, Vanessa, additional, Peake, Jane, additional, Blincoe, Annaliesse, additional, Primhak, Sarah, additional, Stables, Simon, additional, Gibson, Kate, additional, Woon, See-Tarn, additional, Drake, Kylie Marie, additional, Hill, Adrian V.S., additional, Chan, Cheng-Yee, additional, King, Richard, additional, Ameratunga, Rohan, additional, Teiti, Iotefa, additional, Aubry, Maite, additional, Cao-Lormeau, Van-Mai, additional, Tangye, Stuart G., additional, Zhang, Shen-Ying, additional, Jouanguy, Emmanuelle, additional, Gray, Paul, additional, Abel, Laurent, additional, Moreno-Estrada, Andrés, additional, Minster, Ryan L., additional, Quintana-Murci, Lluis, additional, Wood, Andrew C., additional, and Casanova, Jean-Laurent, additional

Published
2022
Full Text
View/download PDF

42. How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper

Author

Neumann, Eva, primary, Schreeck, Filippa, additional, Herberg, Jethro, additional, Jacqz Aigrain, Evelyne, additional, Maitland‐van der Zee, Anke H., additional, Pérez‐Martínez, Antonio, additional, Hawcutt, Daniel B., additional, Schaeffeler, Elke, additional, Rane, Anders, additional, de Wildt, Saskia N., additional, and Schwab, Matthias, additional

Published
2022
Full Text
View/download PDF

43. Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial

Author

Hill, Louise F, primary, Clements, Michelle N, additional, Turner, Mark A, additional, Donà, Daniele, additional, Lutsar, Irja, additional, Jacqz-Aigrain, Evelyne, additional, Heath, Paul T, additional, Roilides, Emmanuel, additional, Rawcliffe, Louise, additional, Alonso-Diaz, Clara, additional, Baraldi, Eugenio, additional, Dotta, Andrea, additional, Ilmoja, Mari-Liis, additional, Mahaveer, Ajit, additional, Metsvaht, Tuuli, additional, Mitsiakos, George, additional, Papaevangelou, Vassiliki, additional, Sarafidis, Kosmas, additional, Walker, A Sarah, additional, Sharland, Michael, additional, Hill, Louise F, additional, Clements, Michelle, additional, Bafadal, Basma, additional, Alarcon Allen, Ana, additional, Anatolitou, Fani, additional, Del Vecchio, Antonio, additional, Giuffrè, Mario, additional, Karachristou, Korina, additional, Manzoni, Paolo, additional, Martinelli, Stefano, additional, Moriarty, Paul, additional, Nika, Angeliki, additional, Papaevangelou, Vana, additional, Roehr, Charles, additional, Sanchez Alcobendas, Laura, additional, Siahanidou, Tania, additional, Tzialla, Chryssoula, additional, Bonadies, Luca, additional, Booth, Nicola, additional, Catalina Morales-Betancourt, Paola, additional, Cordeiro, Malaika, additional, de Alba Romero, Concha, additional, de la Cruz, Javier, additional, De Luca, Maia, additional, Farina, Daniele, additional, Franco, Caterina, additional, Gialamprinou, Dimitra, additional, Hallik, Maarja, additional, Ilardi, Laura, additional, Insinga, Vincenzo, additional, Iosifidis, Elias, additional, Kalamees, Riste, additional, Kontou, Angeliki, additional, Molnar, Zoltan, additional, Nikaina, Eirini, additional, Petropoulou, Chryssoula, additional, Reyné, Mar, additional, Tataropoulou, Kassandra, additional, Triantafyllidou, Pinelopi, additional, Vontzalidis, Adamantios, additional, and Sharland, Mike, additional

Published
2022
Full Text
View/download PDF

50. Outcome associated with prescription of cardiac rehabilitation according to predicted risk after acute myocardial infarction: Insights from the FAST-MI registries

Author

Debiec, Hanna, Dossier, Claire, Letouzé, Eric, Gillies, Christopher, Vivarelli, Marina, Putler, Rosemary, Ars, Elisabet, Jacqz-Aigrain, Evelyne, Elie, Valery, Colucci, Manuela, Debette, Stéphanie, Amouyel, Philippe, Elalaoui, Siham, Sefiani, Abdelaziz, Dubois, Valérie, Kretzler, Matthias, Ballarin, Jose, Emma, Francesco, Sampson, Matthew, Deschênes, Georges, Ronco, Pierre, Ederhy, Stephane, Cohen, Ariel, Boccara, Franck, Aissaoui, Nadia, Elbaz, Meyer, Bonnefoy-Cudraz, Eric, Druelles, Philipe, Andrieu, Stéphane, Angoulvant, Denis, Furber, Alain, Cottin, Yves, Puymirat, Etienne, Bonaca, Marc, Iliou, Marie-Christine, Tea, Victoria, Ducrocq, Grégory, Douard, Hervé, Labrunee, Marc, Plastaras, Philoktimon, Chevallereau, Pierre, Taldir, Guillaume, Bataille, Vincent, Ferrières, Jean, Schiele, François, Simon, Tabassome, Danchin, Nicolas, Centre de Ressources Biologiques APHP-SU (PASS-CRB-APHP-SU), Unité Mixte de Service Production et Analyse de données en Sciences de la vie et en Santé (PASS), and Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Male, Time Factors, MESH: Registries, health care facilities, manpower, and services, [SDV]Life Sciences [q-bio], medicine.medical_treatment, Cardiac rehabilitation, 030204 cardiovascular system & hematology, MESH: Risk Assessment, MESH: Aged, 80 and over, 0302 clinical medicine, Risk Factors, MESH: Risk Factors, Medicine, Registries, MESH: Cardiac Rehabilitation, 030212 general & internal medicine, Myocardial infarction, Atherothrombotic risk stratification, Non-ST Elevated Myocardial Infarction, health care economics and organizations, Cancer, MESH: Treatment Outcome, Aged, 80 and over, MESH: Aged, education.field_of_study, MESH: Middle Aged, Framingham Risk Score, Rehabilitation, nephrotic syndrome, MESH: Polymorphism, Single Nucleotide, Hazard ratio, Score, genetic renal disease, General Medicine, Middle Aged, MESH: Recovery of Function, 3. Good health, In-hospital mortality, Treatment Outcome, Stratification risque athérothrombotique, cardiovascular system, Female, France, Cardiology and Cardiovascular Medicine, medicine.medical_specialty, pediatrics, education, Population, Infarctus du myocarde, Acute myocardial infarction, Mortalité, MESH: Phenotype, Risk Assessment, 03 medical and health sciences, Intensive care, Internal medicine, MESH: Spain, Humans, cardiovascular diseases, Mortality, Réadaptation cardiaque, MESH: ST Elevation Myocardial Infarction, Medical prescription, Aged, focal segmental glomerulosclerosis, genome-wide association study, MESH: Humans, business.industry, MESH: Time Factors, MESH: Italy, Recovery of Function, medicine.disease, MESH: Male, MESH: Quantitative Trait Loci, MESH: Steroids, Confidence interval, MESH: France, MESH: Non-ST Elevated Myocardial Infarction, gene expression, Mortalité hospitalière, ST Elevation Myocardial Infarction, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Nephrotic Syndrome, business, MESH: Female
Abstract

Cardiac rehabilitation is strongly recommended in patients after acute myocardial infarction.To assess cardiac rehabilitation prescription after acute myocardial infarction according to predicted risk, and its association with 1-year mortality, using the FAST-MI registries.We used data from three 1-month French nationwide registries, conducted 5 years apart from 2005 to 2015, including 13130 patients with acute myocardial infarction admitted to coronary or intensive care units. Atherothrombotic risk stratification was performed using the Thrombolysis In Myocardial Infarction Risk Score for Secondary Prevention (TRS-2P). Patients were classified into three categories: Group 1 (low risk; no or one risk indicator; score of 0 or 1); Group 2 (intermediate risk; two risk indicators; score of 2); and Group 3 (high risk; at least three risk indicators; score of≥3).Among the 12291 patients, cardiac rehabilitation prescription was 43.6% (49.9% in Group 1; 43.0% in Group 2; 35.2% in Group 3). Using Cox multivariable analysis, cardiac rehabilitation prescription was associated with lower mortality at 1 year in the overall population (3.8% vs. 8.2%; hazard ratio [HR] 0.72, 95% confidence interval [CI] 0.61-0.85; P0.001). Cardiac rehabilitation was associated with improved 1-year mortality, with homogeneous relative risk reductions in low- and intermediate-risk categories (HR 0.70, 95% CI 0.51-0.94) compared with high-risk patients (HR 0.72, 95% CI 0.59-0.88). In absolute terms, however, mortality decrease associated with cardiac rehabilitation was positively correlated with risk level (Group 1, 0.9% vs. 2.4%; Group 2, 3.0% vs. 4.2%; Group 3, 10.5% vs. 17.3%).Cardiac rehabilitation prescription was inversely correlated with patient risk. A positive association between cardiac rehabilitation and 1-year survival after acute myocardial infarction was present whatever the risk level, but the greatest mortality reduction was observed in high-risk patients.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results